Chan Luke Kar Man, Rao Tanish, Masangcay Paolo, Kuo Samuel Chia Lin, Wan Tai-Tak
Department of Anaesthesia, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
School of Medicine and Dentistry, Griffith University, Queensland, Australia.
J Pain Palliat Care Pharmacother. 2025 Jun;39(2):254-265. doi: 10.1080/15360288.2025.2479481. Epub 2025 Apr 1.
Chronic pancreatitis is a globally prevalent progressive disease, with pain affecting up to 90% of patients, significantly impairing quality of life and leading to high rates of disability, hospitalizations, and opioid dependence. Pain management is crucial in treating chronic pancreatitis, with endoscopic ultrasound-guided celiac plexus block (EUS-CPB) recognized as an interventional option. This systematic review and meta-analysis, following PRISMA guidelines, synthesized data from 12 studies (5 randomized control trials and 7 observational) on the efficacy of EUS-CPB in managing chronic pancreatitis pain. The overall analysis revealed a significant pain relief proportion of 0.64 (n=612) with moderate heterogeneity. Subgroup analyses revealed a proportion of 0.72 in RCTs and 0.59 in observational studies. Common complications included diarrhea and exacerbation of abdominal pain, with no reported mortality. Despite variations in efficacy due to study heterogeneity and patient differences, the findings suggest EUS-CPB as a safe and effective option, with effects lasting weeks to months. Recent studies have demonstrated the applicability of EUS-CPB across ethnically diverse and pediatric populations. However, limitations including small sample sizes and study variability highlight the need for personalized treatment approaches. Future larger randomized sham-controlled trials are recommended to better assess the duration of pain relief and impact on opioid use.
慢性胰腺炎是一种全球流行的进行性疾病,高达90%的患者会出现疼痛,严重损害生活质量,并导致高致残率、高住院率和阿片类药物依赖。疼痛管理在慢性胰腺炎治疗中至关重要,内镜超声引导下腹腔神经丛阻滞(EUS-CPB)被认为是一种干预选择。本系统评价和荟萃分析遵循PRISMA指南,综合了12项研究(5项随机对照试验和7项观察性研究)的数据,以评估EUS-CPB治疗慢性胰腺炎疼痛的疗效。总体分析显示,疼痛缓解比例显著为0.64(n=612),异质性中等。亚组分析显示,随机对照试验中的比例为0.72,观察性研究中的比例为0.59。常见并发症包括腹泻和腹痛加剧,未报告死亡病例。尽管由于研究异质性和患者差异导致疗效存在差异,但研究结果表明EUS-CPB是一种安全有效的选择,效果可持续数周至数月。最近的研究表明EUS-CPB适用于不同种族和儿科人群。然而,包括样本量小和研究变异性在内的局限性凸显了个性化治疗方法的必要性。建议未来进行更大规模的随机假对照试验,以更好地评估疼痛缓解的持续时间以及对阿片类药物使用的影响。